COSTA MESA, Calif.--(BUSINESS WIRE)--May 19, 2006--Synthetic Blood International, Inc. (OTCBB:SYBD - News) today announced treatment of the fourth patient in its eight-patient Phase II proof-of-concept Oxycyte(TM) study in traumatic brain injury. Cerebral oxygen tension following Oxycyte administration was significantly increased in this patient, consistent with the results in the first three patients.
